Antares pharma, inc. (ATRS)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Cash flows from operating activities:
Net loss

-2,356

4,695

1,043

-2,226

-5,539

6,134

-1,936

-4,520

-6,193

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-4,736

-

-6,120

-6,061

-7,656

-6,626

-5,738

-1,506

-6,787

-10,072

-7,186

-9,097

-8,794

-5,635

-6,359

-5,103

-3,408

-5,011

-3,534

-2,807

-74

-153

-1,299

-1,554

-1,380

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Stock-based compensation expense

1,978

1,825

1,645

1,634

1,366

1,272

1,605

1,065

985

1,119

1,087

748

536

633

609

741

535

1,009

998

917

733

726

694

582

621

901

651

431

451

561

490

461

511

383

579

437

471

Depreciation and amortization

570

641

578

660

678

916

601

603

604

584

549

477

494

489

480

477

413

400

400

390

378

351

369

279

224

205

128

85

74

52

102

29

46

46

44

36

40

Other

144

-184

125

87

67

-142

67

63

63

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of premiums and discounts on investment securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3

-4

-3

-2

-3

-2

-1

-0

-1

-2

-15

-

-

-58

-60

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

-3,663

1,138

9,303

-5,145

10,799

3,493

1,413

1,585

608

1,729

1,079

1,180

-1,190

513

-1,734

2,320

37

1,377

112

2,238

694

1,240

-792

-582

2,613

-2,375

-924

2,600

-499

173

-578

1,221

-1,126

556

685

-305

364

Inventories

1,309

-178

1,268

1,857

2,028

667

595

750

655

1,689

96

994

1,525

-648

-735

2,188

-454

766

191

-431

37

1,416

-341

1,228

644

4,656

776

322

-294

115

3

-406

405

550

-70

87

62

Contract assets

1,694

4,536

-86

-660

-997

5,167

-136

-21

-73

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

154

1,502

-1,353

-858

1,364

841

-109

-158

-250

642

-10

166

144

1,000

-2,340

-461

-120

1,250

-824

-175

684

1,393

-100

34

-710

873

-31

177

204

-486

588

193

-118

106

28

-39

60

Deferred costs

-

-

-

-

-

-

-

-

-

-

320

-819

-61

-

-179

91

850

679

-424

-764

-205

224

627

517

169

-

-

-137

147

-

-

167

529

-85

119

422

-668

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

810

0

0

11

-9

0

-9

36

-

-

-

0

Accounts payable

5,479

-3,743

4,162

-3,630

4,137

3,646

911

57

550

-2,224

-19

-418

1,139

-449

-1,765

3,359

1,714

2,247

-1,689

-3,659

-392

2,909

862

61

-1,144

1,141

-928

2,008

307

403

485

-950

787

310

-454

309

200

Accrued expenses and other liabilities

-1,051

2,034

2,411

468

-25

2,872

453

1,803

-99

572

501

-1,176

1,225

-435

-516

-879

1,249

669

160

1,491

-1,415

-384

-1,398

2,943

-939

587

2,078

1,023

-1,155

282

536

358

-490

-

-

-

-

Deferred revenue

310

324

865

-991

520

6

-16

-968

-999

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses and other current liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,147

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-1,446

-2,222

-

-692

1,760

88

3,143

-1,067

-6,140

-1,965

754

-1,289

248

5,774

4,873

-675

-197

-803

802

-1,061

-512

-2,569

2,367

3

-755

-72

Net cash provided by (used in) operating activities

5,580

-1,130

1,697

808

-11,990

-7,162

-78

-4,053

-6,029

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,873

-4,587

-1,516

2,411

-1,278

-1,351

-1,707

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-3,982

-

-3,013

-4,719

-3,963

-2,348

-5,987

-9,204

-10,658

-5,855

-7,338

-6,178

-6,960

-

-

-4,656

-4,043

-

-

-

-

-

-

-

-

Proceeds from sale of assets

-

-

-

-

-

0

0

4,750

2,750

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of equipment, molds, furniture and fixtures

641

1,076

170

713

391

328

190

275

61

288

350

102

427

601

1,723

788

1,766

629

921

2,201

1,889

1,833

1,911

789

128

558

376

1,044

763

831

2,114

105

205

122

56

73

97

Purchases of investment securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

12,011

0

0

9,118

15,089

9,043

3,025

3,008

-

-

-

0

Proceeds from maturities of investment securities

6,000

-

-

-

-

-

-

-

-

-

-

-

-

3,000

6,000

3,000

3,000

0

0

3,000

3,000

3,000

6,000

9,000

6,000

-

-

-

-

3,000

3,000

3,000

3,000

-

-

-

0

Additions to patent rights

-

-

-

-

-

0

21

9

10

18

26

48

9

23

64

6

32

34

48

32

927

527

209

210

42

224

105

51

38

-39

142

119

21

77

40

66

46

Net cash provided by (used in) investing activities

5,359

-21,221

-170

1,787

-391

-328

-211

9,466

2,679

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-144

Cash flows from financing activities:
Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-436

-

4,211

2,205

1,200

-664

-969

-14,272

182

638

3,879

8,000

5,829

-3,794

11,517

1,904

-9,919

-12,881

-8,300

-250

-235

-

-

-

-

Proceeds from issuance of common stock, net

-

0

0

-4

7,785

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

271

3,731

190

134

350

108

75

263

28

146

80

1,209

381

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options and warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

196

1,492

178

1,236

1,570

110

542

103

1,977

4,334

4,684

582

47

454

438

5,079

Taxes paid related to net share settlement of equity awards

597

54

14

655

408

0

408

5

130

-

-

-

-

19

0

29

34

0

19

56

11

0

0

39

115

0

0

0

104

0

0

0

28

-

-

-

0

Net cash (used in) provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

381

-

24

-29

-34

31

-284

43,058

-11

196

1,492

139

1,121

-

-

542

-1

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash

-

-

-

-

-

-

-

-

-

-

-

-

-1

-

-0

0

1

0

-2

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

-326

3,677

176

14,339

7,727

7,222

-333

258

-102

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,334

4,684

554

47

220

21,719

5,079

Effect of exchange rate changes on cash

-

-

-

-

-

0

0

0

1

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

10,613

-18,673

1,703

16,933

-4,654

-268

-622

5,671

-3,451

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0

0

-

11

-0

-6

8

25

-40

7

-19

-0

3

-9

Net decrease in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-4,038

-

-

-

-

-

-

-

-

-

-

1,960

-9

-

7,045

-2,211

-13,971

39,937

-5,813

-194

-1,190

2,239

-16,208

20,260

3,218

Net increase (decrease) in cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,542

-2,796

-

-7,243

19,581

-10,485

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosure of cash flow information:
Cash paid for interest

935

952

872

607

594

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosure of non-cash investing activities:
Purchases of equipment, molds, furniture and fixtures recorded in accounts payable and accrued expenses

1,131

89

775

-293

399

-7

22

-139

173

-53

-179

178

94

-128

-740

-211

1,505

598

-380

-1,330

1,754

592

-606

393

739

-

-

-

-

-

-

-

-

-

-

-

-

Additions to patent rights recorded in accounts payable and accrued expenses

-

-

-

-

-

-

-

6

6

4

-12

-30

48

21

-9

26

6

-

-

14

32

-473

278

374

771

-

-

-

-

-

-

-

-

-

-

-

-